Health Care Market Oversight

## Public Comments 014 United-Amedisys

This document presents written public comments related to the preliminary review of transaction 014 United-Amedisys by Oregon Health Authority (OHA) under the <u>Health Care Market Oversight</u> program. OHA held a public comment period from December 4 to December 18, 2023, and received written comments via email to <a href="mailto:hcmo.info@oha.oregon.gov">hcmo.info@oha.oregon.gov</a>. Comments are presented below in the order received and may include typos or misspellings. Personal contact information for individuals has been removed.

OHA expresses no views on the substance of these comments, and their publication does not constitute an endorsement by OHA of the views expressed.

You can get this document in other languages, large print, braille or a format you prefer free of charge. Contact us by email at <a href="https://document.ncb/hcmo.info@oha.oregon.gov">https://document.ncb/hcmo.info@oha.oregon.gov</a> or by phone at 503-385-5948. We accept all relay calls.

## **Public Comments**

1. Subject: Amedisys

Received 12/18/23

Does antitrust mean nothing anymore?

Just blatantly spitting in our faces now.

## **About HCMO**

The Health Care Market Oversight program reviews proposed heath care business deals to make sure they support statewide goals related to cost, equity, access, and quality. For more info, you can connect with HCMO staff:

Visit our website

Email us at hcmo.info@dhsoha.state.or.us

Subscribe to program updates